**Session Title:** Highlights of the Day III Session  
**Session Type:** Highlights of the Day  
**Track:** Special Session  
**Time:** 7:30 AM - 9:00 AM  
**Location:** E Hall D1

- **Chair**  
  *Gini F. Fleming, MD - Chair*

- **Melanoma/Skin Cancers**  
  *Paul B. Chapman, MD*

- **Lung Cancer**  
  *Leora Horn, MD, MSc*

- **Gastrointestinal (Colorectal) Cancer**  
  *Gunnar Folprecht, MD*

- **Gastrointestinal (Noncolorectal) Cancer**  
  *Milind M. Javle, MD*

- **Genitourinary (Nonprostate) Cancer**  
  *Toni K. Choueiri, MD*

- **Lymphoma**  
  *Sonali M. Smith, MD*

---

**Session Title:** Biology of Basal Cell, Squamous Cell, and Merkel Cell Carcinomas: Implications for Management  
**Session Type:** Education Session  
**Track:** Melanoma/Skin Cancers  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E450

- **Clinical Scenarios and Changes to Practices for the Treatment of Basal Cell Carcinoma**  
  *Caroline Robert, MD, PhD - Chair*

- **Updates to the Biology and Clinical Management of Merkel Cell Carcinoma**  
  *Guilherme Rabinowits, MD*
• New Approaches to Locally Advanced and Metastatic Squamous Cell Carcinoma of the Skin
  Janice M. Mehnert, MD
• Panel Question and Answer

Session Title: Incorporating the Patient's Voice: Patient Engagement in Research
Session Type: Education Session
Track: Health Services Research
Time: 8:00 AM - 9:15 AM
Location: E253
• Challenging Frontiers: Engaging and Empowering Patients in Research
  Ethan M Basch, MD, MSc - Chair
• Advocacy and Stakeholder Engagement in Research: How to Do It
  Lori Frank, PhD
• Social Networking and Technology as Tools for Research and Quality Improvement
  Sue Ziebland, MSc
• Panel Question and Answer

Session Title: Innovative Strategies for Picking Combination Therapy Regimens
Session Type: Education Session
Track: Developmental Therapeutics
Time: 8:00 AM - 9:15 AM
Location: S100a
• Overview and State of the Art for Evaluating Combination Therapies Preclinically
  Ben Ho Park, MD, PhD - Chair
• Combinations Based on Profiling and Heterogeneity
  Matthew James Ellis, MD, BChir, PhD
• Serial versus Parallel Pathway Inhibition: Successes and Toxicity Limits
  Jeffrey R. Infante, MD
• Use of Human Isogenic Cell Line Models to Predict Driver Mutation Effects on Drug Sensitivity or Resistance
  Josh David Lauring, MD, PhD
• Panel Question and Answer

Session Title: Interacting with Family Members of a Patient: Oncologist Perspectives Based on Personal Experiences
Session Type: Education Session
Track: Patient and Survivor Care
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100bc

- **Introduction**  
  *Teresa Gilewski, MD - Chair*
- **Perspectives of an Oncologist: When the Patient with Cancer Is Your Child**  
  *Andrew S. Artz, MD, MS*
- **How My Cancer Changed My Oncology Practice**  
  *Alyssa G. Rieber, MD*
- **Lessons Learned from Personal Loss**  
  *Jamie H. Von Roenn, MD*
- **Panel Question and Answer**

**Session Title:** Pancreatic Cancer: Selecting Initial Treatment Strategies  
**Session Type:** Education Session  
**Track:** Gastrointestinal (Noncolorectal) Cancer  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E354a

- **When Can You Aim for a Cure in Localized Disease?**  
  *Matthew H. G. Katz, MD - Chair*
- **Is There a Role for Radiation in Localized Disease?**  
  *Jerome Carl Landry, MD, MBA*
- **Selecting First-Line Treatment in Metastatic Disease**  
  *Hedy Lee Kindler, MD*
- **Panel Question and Answer**

**Session Title:** Proteomics: Ready for Clinical Translation?  
**Session Type:** Education Session  
**Track:** Tumor Biology  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S404

- **Pathways, Proteomics, and Biomarkers**  
  *Connie R. Jiménez, PhD - Chair*
- **Serum Proteomics for Biomarker Development**  
  *David Paul Carbone, MD, PhD*
- **What Can We Learn from Tumor Proteomics?**  
  *Gordon B. Mills, MD*
• Panel Question and Answer

**Session Title:** Targeting and Tailoring Therapy for Triple-Negative Breast Cancer  
**Session Type:** Education Session  
**Track:** Breast Cancer  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S406

- Novel Targets and Therapeutic Opportunities in Triple-Negative Breast Cancer  
  *Andrew Nicholas James Tutt, PhD, MBChB - Chair*
- Tailoring Chemotherapy for Triple-Negative Breast Cancer  
  *Melinda L. Telli, MD*
- Should a Diagnosis of Triple-Negative Breast Cancer Affect Locoregional Therapy Decision Making?  
  *Meena S. Moran, MD*
- Panel Question and Answer

**Session Title:** Health Services Research  
**Session Type:** Poster Highlights Session  
**Track:** Health Services Research  
**Time:** 8:00 AM - 12:45 PM  
**Display and Networking Time:** 8:00 AM - 11:00 AM  
**Display and Networking Location:** E354b  
**Discussion Time:** 11:30 AM - 12:45 PM  
**Discussion Location:** E253

- **Co-Chair**  
  *Jennifer W. Mack, MD*
- **Co-Chair**  
  *Winson Y. Cheung, MD, MPH*

**Board 1**

- Impact of duration of adjuvant therapy (AT) on cancer survival. (Abstract 6513)  
  *Aalok Kumar*

**Board 2**

- Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy? (Abstract 6514)  
  *Lisa Catherine Barbera*

**Board 3**

- Panel Question and Answer
• Can we accurately identify chemotherapy-related acute care visits in administrative data? (Abstract 6515)  
  Monika K Krzyzanowska  
  Board 4
• Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. (Abstract 6516)  
  Maria Jiang  
  Board 5
• Population-based analysis of treatment receipt in prostate cancer patients who initially pursued active surveillance (AS). (Abstract 6517)  
  Nathan Christopher Sheets  
  Board 6
• Prolonged radiation duration in women with cervical cancer: A population-based analysis of associated factors and impact on survival. (Abstract 6518)  
  Ana Isabel Tergas  
  Board 7
• The toxicity gap: Do real-life patients get hospitalized more during chemotherapy compared to trial patients? (Abstract 6519)  
  Rebecca Michelle Prince  
  Board 8
• Comparison of results between the first and updated reports of phase III clinical trials (RCTs). (Abstract 6520)  
  Elena Elimova  
  Board 9
• Impact of chemotherapy dose and schedule on progression and survival in metastatic breast cancer: A systematic review. (Abstract 6521)  
  Marek S. Poniewierski  
  Board 10
• Adoption of hypofractionated radiotherapy for early-stage invasive breast cancer after publication of randomized trials. (Abstract 6522)  
  Ronald C. Chen  
  Board 11
• A randomized, controlled study comparing NCI’s original and revised informed consent templates. (Abstract 6523)  
  Holly A Massett  
  Board 12
• The use of health-related quality of life outcomes in oncology practice: An international study. (Abstract 6524)  
  Julie Rouette
• Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013. (Abstract 6525)
  *David H. Howard*

• Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. (Abstract 6526)
  *Scott F. Huntington*

• Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC). (Abstract 6527)
  *Daniel A. Goldstein*

• Comparative health care (HC) costs and quality of care in five cancer types by physician office (PO) and hospital outpatient (HOP) settings. (Abstract 6528)
  *Maxine Fisher*

• Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients. (Abstract 6529)
  *Michaela Ann Dinan*

• Patient demand for care: How much does this contribute to inappropriate tests and treatments? (Abstract 6530)
  *Keerthi Gogineni*

• Place of readmission and outcomes after major cancer surgery. (Abstract 6531)
  *Karyn Beth Stitzenberg*

• Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data. (Abstract 6532)
  *Jessica A. Zerillo*

• Decisions about cancer treatment: Matching of actual to preferred roles and patient ratings of care. (Abstract 6533)
  *Kenneth L. Kehl*

• Medicare Part D low-income subsidy and disparities in breast cancer treatment. (Abstract 6534)
Alana Biggers  
Board 24  
• Variation in hospital thromboprophylaxis rates for abdominal cancer surgery. (Abstract 6535) 
  Robert Wallace Krell  
Board 25  
• Sustaining quality cancer care in the NCI Community Cancer Centers Program (NCCCP). (Abstract 6536) 
  Kathleen M. Castro  
Board 26  
• Lymphadenectomy quality measure for colon cancer: Is it working? (Abstract 6537) 
  Jennifer Leigh Paruch  
• Cancer Care Outcomes in the Real World  
  Mariana Chavez-Mac Gregor, MD, MSc  
• Cross Talk: Health Services Research and Clinical Trials  
  Jeffrey M. Peppercorn, MD, MPH  
• Creating Value in Cancer Care  
  Kelvin K. Chan, MD MSc MSc  
• Progress in Cancer Care Quality  
  Monika K Krzyzanowska, MD, MPH, FRCP  
• Panel Question and Answer

Session Title: Lung Cancer - Non-small Cell Metastatic  
Session Type: Poster Highlights Session  
Track: Lung Cancer  
Time: 8:00 AM - 12:45 PM  
Display and Networking Time: 8:00 AM - 11:00 AM  
Display and Networking Location: E354b  
Discussion Time: 11:30 AM - 12:45 PM  
Discussion Location: E450

• Co-Chair  
  Luis Paz-Ares, MD, PhD

• Co-Chair  
  Nathan A. Pennell, MD, PhD  
  Board 27

• Pan-Canadian rash trial with EGFR inhibitors. (Abstract 8013)  
  Barbara L. Melosky
Board 28

- Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303). (Abstract 8014)
  
  Karen L. Reckamp

Board 29

- Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698). (Abstract 8015)
  
  Primo Lara

Board 30

- Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902. (Abstract 8016)
  
  Satoshi Oizumi

Board 31

- Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study. (Abstract 8017)
  
  Yi-Long Wu

Board 32

- Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). (Abstract 8018)
  
  Suresh S. Ramalingam

Board 33

- Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib—LUX-Lung 5 (LL5). (Abstract 8019^)
  
  Martin H. Schuler

Board 34

- Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). (Abstract 8020)
  
  Edward B. Garon

Board 35

- Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. (Abstract 8021^)
  
  Julie R. Brahmer

Board 36
• Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. (Abstract 8022)
  Naiyer A. Rizvi
  Board 37
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. (Abstract 8023)
  Scott Joseph Antonia
  Board 38
• First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. (Abstract 8024)
  Scott N. Gettinger
  Board 40
• Molecular characterization of an extensive lung cancer patient-derived xenograft (PDX) resource. (Abstract 8025)
  Philip C. Mack
  Board 41
• Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. (Abstract 8026)
  Jonathan Wade Goldman
  Board 42
• Rictor amplification to define a novel and unique subset of lung cancer patients. (Abstract 8027)
  Haiying Cheng
  Board 43
• Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma. (Abstract 8028)
  Joline Si Jing Lim
  Board 44
• Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history. (Abstract 8029)
  Alexander E. Drilon
  Board 45
• A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (Abstract 8030^)
  Leora Horn
  Board 46
• Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). (Abstract 8031)
Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers. (Abstract 8032)

Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival. (Abstract 8033)

Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. (Abstract 8034)

A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. (Abstract 8035)

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. (Abstract 8036^)

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) (Abstract 8002)

EGFR Inhibitors: Novel Combinations and the Second Generation

Immune Check Point Inhibitors: Where Are We Now?

Finding More Targets

Hidden Gems

Panel Question and Answer
**Session Title:** Sarcoma  
**Session Type:** Poster Highlights Session  
**Track:** Sarcoma  
**Time:** 8:00 AM - 12:45 PM  
Display and Networking Time: 8:00 AM - 11:00 AM  
Display and Networking Location: S102  
Discussion Time: 11:30 AM - 12:45 PM  
Discussion Location: S100bc

- **Co-Chair**  
  *Breelyn A. Wilky, MD*  
- **Co-Chair**  
  *Vicki Leigh Keedy, MD, MSCI*

**Board 1**  
- Integrate whole genomic study of KIT/PDGFRA wild-type (WT) GIST. (Abstract 10513)  
  *Margherita Nannini*

**Board 2**  
- Disregulation of *mir-550* and *let-7e* in intestinal high-risk localized GIST: A GEIS study. (Abstract 10514)  
  *Jose Antonio Lopez-Guerrero*

**Board 3**  
  *Bruno Vincenzi*

**Board 4**  
- Metabolomic profiling of gastrointestinal stromal tumor (GIST) in human tissue samples and xenografts. (Abstract 10516)  
  *Danny Yakoub*

**Board 5**  
- Improvement of existing risk classifications in primary gastrointestinal stromal tumors (GIST). (Abstract 10517)  
  *Piotr Rutkowski*

**Board 6**  
- Interrelationship of primary and secondary mutations in gastrointestinal stromal tumors during TKI therapy. (Abstract 10518)  
  *Peter Hohenberger*
• Neoadjuvant administration of radiation therapy and intratumoral autologous dendritic cells in patients with localized high-risk soft tissue sarcomas. (Abstract 10519)
  Shailaja KS Raj

• Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. (Abstract 10520)
  Richard D. Carvajal

• Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas. (Abstract 10521)
  Alexander Noor Shoushtari

• PD-L1 expression and immune infiltrates in sarcoma. (Abstract 10522)
  Sandra P. D'Angelo

• Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS). (Abstract 10523)
  Axel Le Cesne

• A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS). (Abstract 10524)
  Shunji Takahashi

• A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS). (Abstract 10525)
  Stefano Ferrari

• NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas. (Abstract 10526)
  Zeynep Eroglu

• Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. (Abstract 10527)
  Mark Andrew Dickson

• Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS). (Abstract 10528)
Herbert H. F. Loong
Board 17

• Long-term follow-up of the CESS 81 and CESS 86 Ewing sarcoma trials. (Abstract 10529)

Herbert Juergens
Board 18

• Survival of adolescents and young adults (AYAs) with skeletal Ewing sarcoma: A Dutch population-based study. (Abstract 10530)

S.E.J. Kaal
Board 19

• Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. (Abstract 10531)

John Andrew Livingston
Board 20

• Results of a randomized prospective clinical trial evaluating maintenance chemotherapy in patients with high-grade, operable osteosarcoma: A report from the Latin American Group of Osteosarcoma Treatment. (Abstract 10532)

Antonio Sergio Petrilli
Board 21

• A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy. (Abstract 10533^)

Giovanni Grignani

• Molecular Discoveries in GIST

Andrew J. Wagner, MD, PhD

• Immunotherapeutic Approaches for Sarcomas

John M. Goldberg, MD

• Earl-Phase Trials in Sarcomas

Jayesh Desai, MBBS, FRACP, MD

• Insights from Studies in Bone Sarcomas

Damon R. Reed, MD

• Panel Question and Answer
Session Title: 50 Years of Progress in Advanced Prostate Cancer
Session Type: Education Session
Track: Genitourinary Cancer
Time: 9:45 AM - 11:00 AM
Location: S100bc

- Hormonal Therapies in Prostate Cancer: The New and the Old
  Cora N. Sternberg, MD, FACP - Chair
- Revising the Role of Chemotherapy in Prostate Cancer
  Daniel Peter Petrylak, MD
- Integrating Immunotherapies in Prostate Cancer Treatment
  Ravi Amrit Madan, MD
- The Evolution of Radiopharmaceuticals in Prostate Cancer
  Chris Parker, MD, MRCP
- Panel Question and Answer

Session Title: Why Is Chemotherapy Here to Stay in Lung Cancer?
Session Type: Education Session
Track: Lung Cancer
Time: 9:45 AM - 11:00 AM
Location: E450

- Chemotherapy: Here to Stay
  Mark G. Kris, MD - Chair
- Predictive Markers for Cytotoxic Chemotherapy
  Jean-Charles Soria, MD, PhD
- Chemotherapy Reinvented: Conjugate Drugs and Nanoparticles
  Thomas E. Stinchcombe, MD
- Panel Question and Answer

Session Title: Colorectal Cancer: Not Just One Disease
Session Type: Clinical Science Symposium
Track: Gastrointestinal (Colorectal) Cancer
Time: 9:45 AM - 11:15 AM
Location: S406

- Chair
  Weijing Sun, MD
• Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). (Abstract 3509)
  Scott Kopetz
• Chair
  Richard H. Wilson, MD
• Analysis of clonal evolution in colorectal cancer. (Abstract 3510)
  Donna M. Graham
• Is the Molecular Profile a Moving Target?
  James M. Ford, MD
• Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. (Abstract 3511)
  Rodrigo Dienstmann
• Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. (Abstract 3512)
  Frank A. Sinicrope
• Should Biology Inform Future Clinical Trial Design?
  Heinz-Josef Lenz, MD

Session Title: Palliative Care: Interventions That Matter
Session Type: Clinical Science Symposium
Track: Patient and Survivor Care
Time: 9:45 AM - 11:15 AM
Location: E253
• Chair
  Teresa Gilewski, MD
• The ENABLE III randomized controlled trial of concurrent palliative oncology care. (Abstract 9512)
  Marie Bakitas
• Care for the Caregivers
  Teresa Gilewski, MD
• Benefits of immediate versus delayed palliative care to informal family caregivers of persons with advanced cancer: Outcomes from the ENABLE III randomized clinical trial. (Abstract LBA9513)
  J Nicholas Dionne-Odom
• Palliative Care: Timing Is Everything
  Jennifer S. Temel, MD
• Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness. (Abstract LBA9514)
Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Session Type: Oral Abstract Session
Track: Breast Cancer
Time: 9:45 AM - 12:45 PM
Location: E Hall D1

- **Chair**
  Tiffany A. Traina, MD
- **Chair**
  Janice Maria Walshe, MD
- Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. (Abstract 1000^)
  Shaveta Vinayak
- Expression of novel immunotherapeutic targets in triple-negative breast cancer. (Abstract 1001)
  Gargi Dan Basu
- RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146. (Abstract 1002)
  Milan Radovich
- Toward Precision Medicine: Searching for Clues
  Shridar Ganesan, MD, PhD
- Panel Question and Answer
- Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. (Abstract 1005)
  Gunter Von Minckwitz
- Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. (Abstract 1020)
  Steven J. Isakoff
- Does pathologic complete response predict for outcome in BRCA mutation carriers with triple-negative breast cancer? (Abstract 1023)
  Shani Paluch-Shimon
• Toward Precision Medicine: Linking Biomarkers to Therapeutics
  
  *Melinda L. Telli, MD*

• Panel Question and Answer
  
  *Panel Discussion*

• Adoption of hypofractionated radiotherapy (HyRT) for ductal carcinoma in situ (DCIS): A SEER-Medicare study. (Abstract 1006)
  *Aaron David Falchook*

• Trends in treatment patterns and outcomes for DCIS patients: A SEER population-based analysis. (Abstract 1007)
  *Mathias Worni*

• Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. (Abstract 1008)
  *Florian Fitzal*

• Toward Precision Medicine: Personalizing Local Therapy
  
  *Julia R. White, MD*

• Panel Question and Answer
  
  *Panel Discussion*

---

**Session Title:** Developmental Therapeutics - Immunotherapy

**Session Type:** Oral Abstract Session

**Track:** Developmental Therapeutics

**Time:** 9:45 AM - 12:45 PM

**Location:** S100a

• Chair
  *David S. Hong, MD*

• Chair
  *John Timmerman, MD*

• Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). (Abstract 3000)
  *Omid Hamid*

• A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. (Abstract 3001^)
  *Jose Lutzky*

• Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. (Abstract 3002^)
  *Neil Howard Segal*

• New Results in PD-1/PD-L1 Blockade
  *Suzanne Louise Topalian, MD*

• Panel Question and Answer
- The neoantigen landscape underlying clinical response to ipilimumab. (Abstract 3003)
  Alexandra Snyder Charen
- Germline genetic determinants of immunotherapy response in metastatic melanoma.
  (Abstract 3004)
  Christina Adaniel
- Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (Abstract 3005^)
  Richard Kefford
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (Abstract 3006^)
  F. Stephen Hodi
- Correlates of Clinical Response to Checkpoint Inhibitors
  Margaret K. Callahan, MD, PhD
- Panel Question and Answer
  Panel Discussion
- A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. (Abstract 3007)
  Neil Howard Segal
- HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. (Abstract LBA3008)
  Christian S. Hinrichs
- New Targets in Immunotherapy
  John Timmerman, MD
- Panel Question and Answer
  Panel Discussion

**Session Title:** Leukemia, Myelodysplasia, and Transplantation

**Session Type:** Oral Abstract Session

**Track:** Leukemia, Myelodysplasia, and Transplantation

**Time:** 9:45 AM - 12:45 PM

**Location:** E354a

- Co-Chair
  Jeffrey E. Lancet, MD
- Chair
  Olatoyosi Odenike, MD
- Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus "7+3" for adults with newly diagnosed acute myeloid leukemia (AML). (Abstract 7002)
  Joshua F. Zeidner
• Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial (Abstract 7026)
  Srdan Verstovsek

• New Treatment Strategies for High-Risk Myeloid Malignancies
  Guido Marcucci, MD

• Panel Question and Answer
  Panel Discussion

• Efficacy of HSV-TK+ suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT): Preliminary results of randomized TK008 study. (Abstract 7003)
  Fabio Ciceri

• Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation—A case-cohort analysis. (Abstract 7004)
  Koen Van Besien

• Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). (Abstract 7005^)
  Max S. Topp

• Cellular and Immune-Based Therapies for Hematologic Malignancies
  Crystal Mackall, MD

• Panel Question and Answer
  Panel Discussion

• Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. (Abstract 7014)
  Susan Mary O’Brien

• Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL). (Abstract 7007)
  Jeff Porter Sharman

• Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. (Abstract LBA7008)
  John C. Byrd

• Novel Therapies in Chronic Lymphocytic Leukemia: Targeting the B-Cell Receptor
  Nicole Lamanna, MD

• Panel Question and Answer